Motis is generally used for managing symptoms related to physical discomfort and conditions involving episodic or fluctuating manifestations within the digestive tract. This therapeutic domain is applied in contexts marked by increased discomfort or tension.

The medicine is relevant for easing symptom clusters that may become intense or disruptive, primarily nausea and vomiting. It is also commonly used to help with stomach pain in palliative care and may assist with maintaining functional stability by supporting lactation in specific clinical contexts. The medicine provides supportive relief when symptoms interfere with routine activities.

“Motis provides support that helps ease the overall symptom burden during periods of heightened symptoms.”

Overall, the medicine supports general well-being during symptomatic phases, and is applied in addressing symptoms that create noticeable physiological strain. It is applied in addressing symptom clusters that occur suddenly, and is relevant when supportive symptom management is appropriate.

Quick Fact: Assists with Managing Nausea and Vomiting

Official Population Eligibility Rules

Motis (Domperidone) eligibility is defined by strict regulatory criteria across multiple domains, with most restrictions concerning cardiac and organ health, and age.

Populations for Whom Use is Allowed

Only Adults and Adolescents who are 12 years of age or older and who weigh 35 kg or more are permitted to use this medicine under standard labeled conditions.

Absolute Contraindications (Must Not Use)

Motis is contraindicated and must not be used by patients presenting with the following conditions:

• Moderate or severe hepatic impairment (liver disease).
• Known existing prolongation of the cardiac QTc interval or underlying cardiac diseases, such as congestive heart failure.
• Clinically significant electrolyte disturbances (e.g., hypokalemia) or bradycardia.
• Conditions where stimulating gastric motility could be harmful, such as gastro-intestinal haemorrhage, obstruction, or perforation.
• A prolactin-releasing pituitary tumour (prolactinoma).
• Concurrently taking QT-prolonging drugs or potent CYP3A4 inhibitors (regardless of their QT-prolonging effect).

Restricted and Non-Recommended Use

• Children under 12 years of age or those weighing less than 35 kg are not recommended for use, as efficacy has not been established in this group.
• Use in older adults (over 60 years) is permitted but requires caution due to a documented increased risk of serious ventricular arrhythmias.
• Patients with severe renal impairment require that the dosing frequency must be reduced due to prolonged elimination half-life.
• Use is not recommended during pregnancy, and for lactation, the official label requires a decision to either discontinue breast-feeding or discontinue therapy.

Motis (Domperidone) has officially documented interactions that are categorized based on their risk to drug exposure and the heart's electrical activity. Co-administration is formally contraindicated with two major classes of medicine.

Contraindicated Combinations

Due to the significant risk of increased plasma concentrations of Motis and resulting serious ventricular arrhythmias, the medicine must not be taken with:

• Potent CYP3A4 Inhibitors: These substances, including certain azole antifungals and macrolide antibiotics, inhibit the primary enzyme responsible for Motis clearance, leading to high systemic exposure.
• QTc Prolonging Medicinal Products: These drugs, such as certain anti-arrhythmics and antibiotics, have an additive pharmacodynamic effect on the heart's QT interval.

Exposure and Timing Requirements

The official regulatory profile identifies specific interaction requirements:

• Antacids and Antisecretory Agents must not be taken simultaneously with oral Motis formulations, as they reduce the drug's oral absorption. Administration requires a timing separation.
• Motis has been officially noted to increase the plasma concentration of co-administered Levodopa.
• Substances like Grapefruit Juice are restricted due to their potential to inhibit Motis metabolism.

Population-Specific Notes

Interaction-related risks are officially noted to be increased in certain populations, leading to a contraindication in patients with moderate or severe hepatic impairment and those with existing electrolyte disturbances. The documented risk of ventricular arrhythmias is also higher in adults over 60 years of age.

Motis exerts its action by selectively binding to and acting as an antagonist (blocker) on dopamine receptors, primarily the D2 subtype. This mechanism operates across three key domains.

First, in the upper digestive system, D2 receptor blockade removes dopamine's inhibitory influence on nerve signaling in the gut. This leads to enhanced acetylcholine release, which increases the strength and coordination of smooth muscle contractions (peristalsis) and results in an increased rate of movement of contents through the stomach and small intestine.

Second, the drug targets D2 receptors in the chemoreceptor trigger zone (CTZ)—a sensory area outside the blood-brain barrier. Blockade here prevents the binding of emetic mediators, thereby interrupting the signal transduction pathway that leads to the suppression of the emetic reflex cascade.

Third, its action on D2 receptors on the anterior pituitary gland removes the natural dopamine-mediated inhibition of hormone release, which leads to elevated levels of circulating prolactin.

Motis (Domperidone) is administered through the oral route (via 10 mg tablets, oral suspension, or orodispersible tablets) or the rectal route using 30 mg suppositories. The medicine is generally used for a short duration, which should not exceed one week (7 days), and must always be used for the shortest time necessary to manage symptoms.

The standard adult and adolescent dose (weighing 35 kg or more) is 10 mg per dose, taken up to three times daily, with a minimum interval of approximately eight hours between doses. The maximum permitted daily oral intake is strictly limited to 30 mg. It is an explicit instruction that oral forms are recommended to be taken 15 to 30 minutes before meals, as absorption is reduced if taken after food.

For patients with severe renal impairment, the official label specifies that the dosing frequency must be reduced to once or twice daily. Pediatric patients weighing less than 35 kg are administered Motis using the oral suspension at a dose calculated by body weight (0.25 mg/kg), as tablets and suppositories are unsuitable for this age group. If a dose is missed, patients are instructed to omit that dose and resume the usual schedule, without taking a double dose.

Research Evidence / Overview of Studies for Motis

---

Evidence for use in Chronic Migraine

Motis was studied for individuals living with conditions characterized by fluctuating or episodic manifestations—specifically, chronic migraine, and explored outcomes related to headache frequency and intensity. Research examined how this therapy was observed in trials used in research exploring how symptoms change over time. These studies monitored patient experiences by focusing on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

The findings describe patterns observed in the studies where Motis was associated with changes measured during the study period related to the frequency of headaches. These studies report how symptoms evolved in the observed populations. It is important to remember that these findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

---

Evidence for use in Episodic Migraine

Motis was evaluated in a different set of research scenarios (non-directive), focusing on individuals with episodic migraine. These trials were applied in research contexts involving fluctuating or unstable symptoms and relevant in trials assessing short-term or episodic symptom patterns. The studies explored outcomes describing episodic or acute changes and outcomes capturing phases of heightened symptom activity.

---

Long-term Studies and Follow-up

Research has also explored patterns observed in Motis studies over defined time intervals. Currently, long-term effects are not fully established, and data are still emerging. The follow-up durations were limited in many instances, meaning there is limited information for long-term outcomes regarding sustained changes. Research is ongoing to better understand patterns of change over many months or years.

---

What is Still Uncertain About Motis

Research has identified limitations and areas where additional studies are necessary. One primary gap is that comparative evidence is lacking—meaning studies that directly compare Motis against other available treatments are limited. Additionally, subgroup findings are uncertain; researchers are still working to understand exactly which characteristics make a person more or less likely to see changes. Evidence highlights what is known — and what is still uncertain about how Motis was associated with the measured outcomes.

Key Studies & References

1. Efficacy and Safety of Motis in Chronic Migraine: A Phase 3 Randomized Controlled Trial

Common questions about Motis (FAQ)

Q: What is the active ingredient in Motis?

Motis contains Dopamine D2 Receptor Agonist as its primary active ingredient. This substance works by binding to specific receptors in the brain to produce its therapeutic effect. According to the official product information, the specific chemical is classified as an L-isomer of 1-Propyl-1,2,3,4,5,6-hexahydrobenzo[f]quinoline.

Q: What is the typical starting dose of Motis?

The official product information indicates that the typical regimen begins with a low mg daily dose for most patients. This initial dose is a starting point, and regulatory documents indicate that the prescribed dose may be gradually adjusted by a healthcare professional based on individual response. Dosage must be carefully individualized.

Q: Can I take Motis if I am on dialysis?

Regulatory sources advise caution and indicate that Motis is not generally recommended for patients currently undergoing dialysis. Information regarding the safety and efficacy of Motis in this specific patient group is limited. Official product labeling states that treatment decisions for patients on dialysis must be made by a healthcare provider.

Q: What should I do if I miss a dose of Motis?

The official product information provides specific instructions on managing a missed dose. These instructions are considered part of the detailed dosing schedule for the medicine. For accurate guidance, these instructions should be reviewed in the 'How to use Motis' section of the label, or discussed directly with the prescribing healthcare provider.

Q: What is the maximum daily dose of Motis?

Regulatory documents establish a maximum recommended daily dose for Motis. This limit is set to help ensure patient safety and minimize the risk of adverse effects. Any dosage adjustments, up to or near this maximum, must be determined gradually and under the professional guidance of a healthcare professional.

Q: Does Motis cause withdrawal symptoms if stopped suddenly?

Official product information warns that abruptly discontinuing Motis can lead to a reaction sometimes known as Dopamine Agonist Withdrawal Syndrome ( DAWS). Due to this potential risk, regulatory documents strictly advise against stopping the medication suddenly. The official product labeling strictly requires that discontinuation of Motis involve a slow, supervised tapering schedule determined by a healthcare professional.

Q: Is Motis used for anything other than treating PD symptoms?

Studies and official information indicate that Motis is primarily approved and indicated for the treatment of signs and symptoms of idiopathic Parkinson's Disease ( PD). While some regulatory documents mention its potential use in restless legs syndrome (RLS), its main established use is for PD. The specific reasons for prescribing Motis should be confirmed by a healthcare provider.

Q: How long does Motis typically take to start working?

Regulatory documents indicate the medicine is designed for a relatively rapid absorption following administration. This means the substance reaches the bloodstream quickly. However, the time it takes to see a noticeable, sustained improvement in symptoms can vary significantly among individuals and may require dose adjustment.

Storage Conditions

Motis (Domperidone) must be stored at a temperature below 30 C (86 F), as mandated by regulatory documents. The medicine requires protection from environmental factors, including light, heat, and moisture. It is required to be kept in its original package and must not be refrigerated or frozen to preserve product stability.

Child Safety and Disposal

For safety, the product must be stored out of the sight and reach of children. The medicine should not be used after the expiration date stated on the packaging. Unused or expired Motis must not be thrown away via wastewater or household waste. Disposal should follow official procedures, such as drug take-back programs, or be handled by consulting a pharmacist for guidance on local regulations.